Syma Iqbal, MD, discusses determining whether to start with regorafenib (Stivarga) or trifluridine/tipiracil (TAS-102; Lonsurf) in metastatic colorectal cancer (mCRC).
Syma Iqbal, MD, assistant professor, Division of Oncology, assistant program director, Fellowship Program, Department of Oncology, educational officer, Division of Oncology, co-director, Liver Cancer Program, Norris Comprehensive Cancer Center, Keck Medicine of USC, discusses determining whether to start with regorafenib (Stivarga) or trifluridine/tipiracil (TAS-102; Lonsurf) in metastatic colorectal cancer (mCRC).
Sequencing of therapies for patients with mCRC remains a challenging decision that requires more attention, Iqbal explains. This is particularly true in the later-line settings where patients can receive regorafenib or TAS-102.
Data strongly support the use of appropriately dosed regorafenib before TAS-102 for patients with mCRC who have good performance status and adequate albumin, Iqbal says. Moreover, patients with refractory mCRC who receive regorafenib first tend to have better outcomes compared with patients who start TAS-102 first, Iqbal concludes.